kynurenic acid has been researched along with Huntington Disease in 20 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 7.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 3.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| " However, using a comprehensive panel of behavioral tests, we demonstrate that the chronic dosing of a selective KMO inhibitor does not significantly modify behavioral phenotypes or natural progression in mouse models of HD." | 1.43 | The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. ( Beaumont, V; Bradaia, A; Deisemann, H; Dijkman, U; Dominguez, C; Ebneth, A; Freije, R; Gelman, S; Gleyzes, M; Heikkinen, T; Heins, M; Javier, RM; Khetarpal, V; Kontkanen, O; Lehtimäki, K; Mrzljak, L; Munoz-Sanjuan, I; Neagoe, I; Park, LC; Puoliväli, J; Rassoulpour, A; Steidl, E; Toledo-Sherman, L; Tombaugh, G; Winkler, D, 2016) |
| "Methylene blue (MB), has been shown to modulate aggregation of amyloidogenic disease proteins." | 1.38 | Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. ( Agrawal, N; Aron, R; Finkbeiner, S; Glabe, C; Lau, A; Lotz, GP; Marsh, JL; Muchowski, PJ; Necula, M; Sontag, EM; Thompson, LM; Tran, A; Yang, G, 2012) |
| " As it did not induce any appreciable side-effect at the protective dose applied in a chronic dosing regime in this mouse model, it appears worthy of further thorough investigations with a view to eventual clinical trials." | 1.37 | Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. ( Freund, TF; Fülöp, F; Klivényi, P; Nyiri, G; Szatmári, I; Szonyi, A; Toldi, J; Vécsei, L; Zádori, D, 2011) |
| "In a transgenic mouse model of Alzheimer's disease, JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss." | 1.37 | Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. ( Adame, A; Andrews-Zwilling, Y; Flik, G; Giorgini, F; Guidetti, P; Hsieh, EW; Huang, SY; Huang, Y; Laue, G; Lee, J; Louie, JY; Masliah, E; Moussaoui, S; Muchowski, JM; Muchowski, PJ; Notarangelo, FM; Patrick, C; Rassoulpour, A; Sathyasaikumar, KV; Scearce-Levie, K; Schwarcz, R; Truong, J; Wu, HQ; Wu, T; Zwilling, D, 2011) |
| "Probenecid treatment significantly reduced the neuronal loss and the number of neuronal intranuclear aggregates." | 1.35 | Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. ( Klivenyi, P; Vamos, E; Vecsei, L; Voros, K; Zadori, D, 2009) |
| "Huntington's disease is a neurological disorder characterised by a progressive chorea and dementia." | 1.28 | Increase in kynurenic acid in Huntington's disease motor cortex. ( Carlà, V; Connick, JH; Moroni, F; Stone, TW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 2 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Beaumont, V | 1 |
| Mrzljak, L | 1 |
| Dijkman, U | 1 |
| Freije, R | 1 |
| Heins, M | 1 |
| Rassoulpour, A | 2 |
| Tombaugh, G | 1 |
| Gelman, S | 1 |
| Bradaia, A | 1 |
| Steidl, E | 1 |
| Gleyzes, M | 1 |
| Heikkinen, T | 1 |
| Lehtimäki, K | 1 |
| Puoliväli, J | 1 |
| Kontkanen, O | 1 |
| Javier, RM | 1 |
| Neagoe, I | 1 |
| Deisemann, H | 1 |
| Winkler, D | 1 |
| Ebneth, A | 1 |
| Khetarpal, V | 1 |
| Toledo-Sherman, L | 1 |
| Dominguez, C | 1 |
| Park, LC | 1 |
| Munoz-Sanjuan, I | 1 |
| Vamos, E | 1 |
| Voros, K | 1 |
| Zadori, D | 2 |
| Vecsei, L | 2 |
| Klivenyi, P | 2 |
| Nyiri, G | 1 |
| Szonyi, A | 1 |
| Szatmári, I | 1 |
| Fülöp, F | 1 |
| Toldi, J | 1 |
| Freund, TF | 1 |
| Campesan, S | 1 |
| Green, EW | 1 |
| Breda, C | 1 |
| Sathyasaikumar, KV | 2 |
| Muchowski, PJ | 3 |
| Schwarcz, R | 6 |
| Kyriacou, CP | 1 |
| Giorgini, F | 2 |
| Zwilling, D | 1 |
| Huang, SY | 1 |
| Notarangelo, FM | 1 |
| Guidetti, P | 5 |
| Wu, HQ | 1 |
| Lee, J | 1 |
| Truong, J | 1 |
| Andrews-Zwilling, Y | 1 |
| Hsieh, EW | 1 |
| Louie, JY | 1 |
| Wu, T | 1 |
| Scearce-Levie, K | 1 |
| Patrick, C | 1 |
| Adame, A | 1 |
| Moussaoui, S | 1 |
| Laue, G | 1 |
| Flik, G | 1 |
| Huang, Y | 1 |
| Muchowski, JM | 1 |
| Masliah, E | 1 |
| Sontag, EM | 1 |
| Lotz, GP | 1 |
| Agrawal, N | 1 |
| Tran, A | 1 |
| Aron, R | 1 |
| Yang, G | 1 |
| Necula, M | 1 |
| Lau, A | 1 |
| Finkbeiner, S | 1 |
| Glabe, C | 1 |
| Marsh, JL | 1 |
| Thompson, LM | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Luthi-Carter, RE | 1 |
| Augood, SJ | 1 |
| Sapko, MT | 1 |
| Yu, P | 1 |
| Tagle, DA | 1 |
| Pellicciari, R | 1 |
| Bates, GP | 1 |
| Graham, RK | 1 |
| Hayden, MR | 1 |
| Leavitt, BR | 1 |
| MacDonald, ME | 1 |
| Slow, EJ | 1 |
| Wheeler, VC | 1 |
| Woodman, B | 1 |
| Perez-De La Cruz, V | 1 |
| Santamaria, A | 1 |
| Jauch, D | 1 |
| Bird, ED | 3 |
| Vonsattel, JP | 1 |
| Whetsell, WO | 1 |
| Harris, CA | 1 |
| Miranda, AF | 1 |
| Tanguay, JJ | 1 |
| Boegman, RJ | 1 |
| Beninger, RJ | 1 |
| Jhamandas, K | 1 |
| Reynolds, GP | 1 |
| Pearson, SJ | 1 |
| Beal, MF | 2 |
| Matson, WR | 2 |
| Storey, E | 1 |
| Milbury, P | 1 |
| Ryan, EA | 1 |
| Ogawa, T | 1 |
| Swartz, KJ | 1 |
| Gamache, PH | 1 |
| Connick, JH | 2 |
| Carlà, V | 2 |
| Moroni, F | 2 |
| Stone, TW | 2 |
4 reviews available for kynurenic acid and Huntington Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
Topics: Animals; Calcium; Cell Death; Disease Models, Animal; Energy Metabolism; Excitatory Amino Acids; Hum | 2007 |
16 other studies available for kynurenic acid and Huntington Disease
| Article | Year |
|---|---|
The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Brain; Disease Models, Anima | 2016 |
Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
Topics: Age Factors; Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose | 2009 |
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Humans; | 2011 |
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Huntington | 2011 |
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain Chemistry; Disease Models, Animal; Female; H | 2011 |
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Topics: Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; | 2012 |
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
Topics: Aged; Analysis of Variance; Cerebellum; Cerebral Cortex; Frontal Lobe; Humans; Huntington Disease; K | 2004 |
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Topics: Animals; Brain Chemistry; Excitatory Amino Acid Agonists; Huntington Disease; Kainic Acid; Kynurenic | 2006 |
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Topics: Age Factors; Animals; Brain Chemistry; Chromatography, Gas; Chromatography, High Pressure Liquid; Di | 2006 |
Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.
Topics: Aged; Brain; Brain Chemistry; Female; Humans; Huntington Disease; Kinetics; Kynurenic Acid; Lyases; | 1995 |
Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Topics: Alanine; Animals; Anticonvulsants; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism | 1998 |
Neurochemical abnormalities in Huntington's disease: neurotoxic mechanisms and neurotransmitter changes.
Topics: Brain Chemistry; Humans; Huntington Disease; Kynurenic Acid; Neurotransmitter Agents | 1992 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |
Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
Topics: Aged; Autopsy; Corpus Striatum; Female; Humans; Huntington Disease; Kynurenic Acid; Kynurenine; Male | 1990 |
Increase in kynurenic acid in Huntington's disease motor cortex.
Topics: Aged; Caudate Nucleus; Frontal Lobe; Globus Pallidus; Humans; Huntington Disease; Kynurenic Acid; Mi | 1989 |
Increased kynurenic acid levels in Huntington's disease.
Topics: Brain Chemistry; Humans; Huntington Disease; Kynurenic Acid | 1988 |